Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized study (phase I closed) of radiation therapy and temozolomide versus radiation therapy and nitrosourea [carmustine, lomustine] for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (astrocytoma dominant)

Next Previous
X
Search
Trial Profile

A phase III randomized study (phase I closed) of radiation therapy and temozolomide versus radiation therapy and nitrosourea [carmustine, lomustine] for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (astrocytoma dominant)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary) ; Lomustine (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 May 2018 Status changed from active, no longer recruiting to completed.
    • 21 Dec 2017 Planned End Date changed from 1 Mar 2020 to 1 Feb 2020.
    • 07 Jun 2016 Results examining the prognostic value of mutations within IDH1/2, ATRX, CIC, FUBP1, and the TERT promoter in a phase III study of grade III astrocytomas using multivariate analyses presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top